Lumera Licenses Helix Biopharma Technology in Bid to Enter Protein Array Market | GenomeWeb

NEW YORK, Jan. 25 (GenomeWeb News) - Lumera said today that it has acquired the exclusive rights to protein surface chemistry from Helix Biopharma in order to further its development of a proteomic microarray.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.